These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1840 related articles for article (PubMed ID: 28263568)

  • 1. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
    Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
    Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing.
    Liu J; Shui SL
    J Control Release; 2016 Dec; 244(Pt A):83-97. PubMed ID: 27865852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral Delivery Systems for CRISPR.
    Xu CL; Ruan MZC; Mahajan VB; Tsang SH
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
    Tang H; Zhao X; Jiang X
    Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in CRISPR/Cas9 Technology for in Vivo Translation.
    Çiçek YA; Luther DC; Kretzmann JA; Rotello VM
    Biol Pharm Bull; 2019; 42(3):304-311. PubMed ID: 30828060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
    Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9: at the cutting edge of hepatology.
    Pankowicz FP; Jarrett KE; Lagor WR; Bissig KD
    Gut; 2017 Jul; 66(7):1329-1340. PubMed ID: 28487442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
    Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
    Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
    Song M
    Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.